{
  "paper_id": "PMC9631668",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631668/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1.",
      "caption": "Risk of ICH in patients with primary or metastatic brain cancer treated with or without anticoagulants.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c20/9631668/8cc268c82cf2/advancesADV2022008086f1.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c20/9631668/8cc268c82cf2/advancesADV2022008086f1.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c20/9631668/8cc268c82cf2/advancesADV2022008086f1.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c20/9631668/8cc268c82cf2/advancesADV2022008086f1.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c20/9631668/8cc268c82cf2/advancesADV2022008086f1.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9631668/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c20/9631668/8cc268c82cf2/advancesADV2022008086f1.jpg"
    }
  },
  "claims": [
    {
      "sentence": "The flow diagram of the literature search is shown in supplemental Figure 1, and the main features of the studies are reported in Table 1 and supplemental Tables 1 and 3.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Bias assessment plots are reported in supplemental Figure 2A.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Rates of ICH, major ICH, and fatal ICH in patients with primary brain cancer or brain metastases\n\n\n\nOutcome\nNo. of studies\nNo. of ICH/no. of patients\nRate\n95% CI\n\nI\n2\n\n\n\n\nOverall ICH\n30\n445/3893\n7.7%\n5.1-11.5\n92.8%\n\n\nMajor ICH\n7\n117/1287\n6.2%\n2.8-13.0\n91.5%\n\n\nFatal ICH\n11\n13/764\n2.9%\n1.7-4.7\n0%\n\n\nICH in PBC patients\n18\n156/2353\n6.4%\n4.1-9.9\n84.4%\n\n\nICH in MBC patients\n9\n218/1009\n13.0%\n6.5-24.2\n93.7%\n\n\nMajor ICH in PBC patients\n4\n30/793\n3.9%\n1.3-11.6\n87.6%\n\n\nMajor ICH in MBC patients\n3\n87/494\n15.4%\n9.4-24.2\n74.6%\n\n\nICH in patients with VTE\n25\n384/3313\n7.1%\n4.4-11.5\n93.7%\n\n\n\nOpen in a new tab\nMBC, metastatic brain cancer; PBC, primary brain cancer.Rates of ICH in patients with primary brain cancer were reported in 18 studies and ranged from 1.1% to 25.4%.4,9-12,16,18-21,23,27,28,30,31,33-35 The weighted incidence rate was 6.4% (95% CI, 4.1-9.9; I2 = 84.4%; 156 events in 2353 patients) (supplemental Figure 3A), and the risk of publication bias was significant (t = 2.39; P = .03) (supplemental Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Rate of ICH in patients with metastatic brain cancer was reported in 9 studies and ranged from 2.7% to 47.6%.3,5,9,12,14-16,18,26 In these studies, the weighted incidence rate of ICH was 13.0% (95% CI, 6.5-24.2; I2 = 93.7%; 218 events in 1009 patients) (supplemental Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The risk of publication bias was significant (t = 5.10; P = .001); after the trim-and-fill procedure, 2 studies were trimmed, and the adjusted rate of ICH was 17.5% (95% CI, 9.6-29.8) (supplemental Figure 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In patients with primary brain cancer, anticoagulant therapy was associated with an increased risk of ICH and of major ICH (Figure 1; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rates of ICH in patients with primary brain cancer or brain metastases treated with or without anticoagulants\n\n\n\nSetting\nNo. of studies\nNo. of ICH/no. of patients treated\nAnticoagulant therapy\nNo. of ICH/no. of patients not treated\nNo anticoagulant therapy\nRR\n95% CI\n\nP\n\n\nI\n2\n\n\n\n\nOverall patients\n17\n152/1072\n11.5%(95% CI, 7.4-17.6)\n177/1824\n6.0%(95% CI, 3.0-11.5)\n1.81\n1.15-2.84\n.001\n60.3%\n\n\nPatients with PBC\n11\n80/659\n12.5%(95% CI, 8.0-18.8)\n50/1346\n4.4%(95% CI, 2.5-7.7)\n2.58\n1.59-4.19\n<.001\n45.5%\n\n\nPatients with MBC\n4\n61/265\n14.7%(95% CI, 4.4-39.2)\n81/301\n15.4%(95% CI, 5.3-37.2)\n0.86\n0.45-1.65\n.287\n0%\n\n\nPatients treated with DOACs vs LMWH\n5\n12/172\n8.3%(95% CI, 4.4-15.3)\n71/278\n11.7%(95% CI, 2.9-37.0)\n0.44\n0.25-0.79\n.007\n0%\n\n\nPatients treated with LMWH vs warfarin\n4\n15/211\n5.9%(95% CI, 1.5-20.5)\n8/198\n5.4%(95% CI, 1.5-17.3)\n1.45\n0.56-3.79\n.185\n0%\n\n\nOverall major ICH\n4\n33/239\n10.4%(95% CI, 4.0-24.5)\n47/734\n3.4%(95% CI, 0.6-17.6)\n1.93\n0.79-4.73\n.001\n38.7%\n\n\nMajor ICH in patients with PBC\n3\n9/135\n6.3%(95% CI, 1.7-20.3)\n9/545\n1.8%(95% CI, 0.9-3.4)\n3.75\n1.6-4.5\n.003\n0%\n\n\n\nOpen in a new tab\nMBC, metastatic brain cancer; PBC, primary brain cancer.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rate of ICH according to the type of anticoagulant treatment\nIn patients with primary brain cancer or brain metastases, DOACs were associated with a lower risk of ICH than low-molecular weight heparin (LMWH) (8.3% vs 11.7%; RR, 0.44; 95% CI, 0.25-0.79; I2 = 0%; 5 studies in 450 patients) (supplemental Figure 4A).8-10,14,17 In patients with primary brain cancer, DOACs were associated with a reduced risk of ICH (RR, 0.19; 95% CI, 0.04-0.99; I2 = 0%; 0 events in 69 DOAC-treated patients and 19 events in 95 LMWH-treated patients, 4 studies).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "When considering only studies in patients receiving anticoagulants for VTE, the RR for ICH was 0.36 (95% CI, 0.18-0.71; I2 = 0%; 4 studies) in patients treated with DOACs (8 events in 131 patients) compared with LMWH (64 events in 223 patients).9,11,14,16 Risk of ICH was not significantly different with LMWH vs warfarin (4 studies, 15 events in 211 LMWH-treated patients vs 8 events in 198 warfarin-treated patients) (RR, 1.45; 95% CI, 0.56-3.79; I2 = 0%) (supplemental Figure 4B).17,22,23,27Discussion\nThe current meta-analysis provides the following findings: (1) the rate of ICH and major ICH is higher in patients with metastatic brain cancer compared with those with primary brain cancer; (2) anticoagulant therapy is associated with an increase in ICH and major ICH in patients with primary brain cancer but not in those with brain metastases; and (3) the risk of ICH is lower in patients with primary or metastatic brain cancer treated with DOACs compared with those treated with LMWH.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The flow diagram of the literature search is shown in supplemental Figure 1, and the main features of the studies are reported in Table 1 and supplemental Tables 1 and 3.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Bias assessment plots are reported in supplemental Figure 2A.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Rates of ICH, major ICH, and fatal ICH in patients with primary brain cancer or brain metastases\n\n\n\nOutcome\nNo. of studies\nNo. of ICH/no. of patients\nRate\n95% CI\n\nI\n2\n\n\n\n\nOverall ICH\n30\n445/3893\n7.7%\n5.1-11.5\n92.8%\n\n\nMajor ICH\n7\n117/1287\n6.2%\n2.8-13.0\n91.5%\n\n\nFatal ICH\n11\n13/764\n2.9%\n1.7-4.7\n0%\n\n\nICH in PBC patients\n18\n156/2353\n6.4%\n4.1-9.9\n84.4%\n\n\nICH in MBC patients\n9\n218/1009\n13.0%\n6.5-24.2\n93.7%\n\n\nMajor ICH in PBC patients\n4\n30/793\n3.9%\n1.3-11.6\n87.6%\n\n\nMajor ICH in MBC patients\n3\n87/494\n15.4%\n9.4-24.2\n74.6%\n\n\nICH in patients with VTE\n25\n384/3313\n7.1%\n4.4-11.5\n93.7%\n\n\n\nOpen in a new tab\nMBC, metastatic brain cancer; PBC, primary brain cancer.Rates of ICH in patients with primary brain cancer were reported in 18 studies and ranged from 1.1% to 25.4%.4,9-12,16,18-21,23,27,28,30,31,33-35 The weighted incidence rate was 6.4% (95% CI, 4.1-9.9; I2 = 84.4%; 156 events in 2353 patients) (supplemental Figure 3A), and the risk of publication bias was significant (t = 2.39; P = .03) (supplemental Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Rate of ICH in patients with metastatic brain cancer was reported in 9 studies and ranged from 2.7% to 47.6%.3,5,9,12,14-16,18,26 In these studies, the weighted incidence rate of ICH was 13.0% (95% CI, 6.5-24.2; I2 = 93.7%; 218 events in 1009 patients) (supplemental Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The risk of publication bias was significant (t = 5.10; P = .001); after the trim-and-fill procedure, 2 studies were trimmed, and the adjusted rate of ICH was 17.5% (95% CI, 9.6-29.8) (supplemental Figure 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In patients with primary brain cancer, anticoagulant therapy was associated with an increased risk of ICH and of major ICH (Figure 1; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rates of ICH in patients with primary brain cancer or brain metastases treated with or without anticoagulants\n\n\n\nSetting\nNo. of studies\nNo. of ICH/no. of patients treated\nAnticoagulant therapy\nNo. of ICH/no. of patients not treated\nNo anticoagulant therapy\nRR\n95% CI\n\nP\n\n\nI\n2\n\n\n\n\nOverall patients\n17\n152/1072\n11.5%(95% CI, 7.4-17.6)\n177/1824\n6.0%(95% CI, 3.0-11.5)\n1.81\n1.15-2.84\n.001\n60.3%\n\n\nPatients with PBC\n11\n80/659\n12.5%(95% CI, 8.0-18.8)\n50/1346\n4.4%(95% CI, 2.5-7.7)\n2.58\n1.59-4.19\n<.001\n45.5%\n\n\nPatients with MBC\n4\n61/265\n14.7%(95% CI, 4.4-39.2)\n81/301\n15.4%(95% CI, 5.3-37.2)\n0.86\n0.45-1.65\n.287\n0%\n\n\nPatients treated with DOACs vs LMWH\n5\n12/172\n8.3%(95% CI, 4.4-15.3)\n71/278\n11.7%(95% CI, 2.9-37.0)\n0.44\n0.25-0.79\n.007\n0%\n\n\nPatients treated with LMWH vs warfarin\n4\n15/211\n5.9%(95% CI, 1.5-20.5)\n8/198\n5.4%(95% CI, 1.5-17.3)\n1.45\n0.56-3.79\n.185\n0%\n\n\nOverall major ICH\n4\n33/239\n10.4%(95% CI, 4.0-24.5)\n47/734\n3.4%(95% CI, 0.6-17.6)\n1.93\n0.79-4.73\n.001\n38.7%\n\n\nMajor ICH in patients with PBC\n3\n9/135\n6.3%(95% CI, 1.7-20.3)\n9/545\n1.8%(95% CI, 0.9-3.4)\n3.75\n1.6-4.5\n.003\n0%\n\n\n\nOpen in a new tab\nMBC, metastatic brain cancer; PBC, primary brain cancer.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rate of ICH according to the type of anticoagulant treatment\nIn patients with primary brain cancer or brain metastases, DOACs were associated with a lower risk of ICH than low-molecular weight heparin (LMWH) (8.3% vs 11.7%; RR, 0.44; 95% CI, 0.25-0.79; I2 = 0%; 5 studies in 450 patients) (supplemental Figure 4A).8-10,14,17 In patients with primary brain cancer, DOACs were associated with a reduced risk of ICH (RR, 0.19; 95% CI, 0.04-0.99; I2 = 0%; 0 events in 69 DOAC-treated patients and 19 events in 95 LMWH-treated patients, 4 studies).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "When considering only studies in patients receiving anticoagulants for VTE, the RR for ICH was 0.36 (95% CI, 0.18-0.71; I2 = 0%; 4 studies) in patients treated with DOACs (8 events in 131 patients) compared with LMWH (64 events in 223 patients).9,11,14,16 Risk of ICH was not significantly different with LMWH vs warfarin (4 studies, 15 events in 211 LMWH-treated patients vs 8 events in 198 warfarin-treated patients) (RR, 1.45; 95% CI, 0.56-3.79; I2 = 0%) (supplemental Figure 4B).17,22,23,27Discussion\nThe current meta-analysis provides the following findings: (1) the rate of ICH and major ICH is higher in patients with metastatic brain cancer compared with those with primary brain cancer; (2) anticoagulant therapy is associated with an increase in ICH and major ICH in patients with primary brain cancer but not in those with brain metastases; and (3) the risk of ICH is lower in patients with primary or metastatic brain cancer treated with DOACs compared with those treated with LMWH.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The flow diagram of the literature search is shown in supplemental Figure 1, and the main features of the studies are reported in Table 1 and supplemental Tables 1 and 3.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Bias assessment plots are reported in supplemental Figure 2A.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Rates of ICH, major ICH, and fatal ICH in patients with primary brain cancer or brain metastases\n\n\n\nOutcome\nNo. of studies\nNo. of ICH/no. of patients\nRate\n95% CI\n\nI\n2\n\n\n\n\nOverall ICH\n30\n445/3893\n7.7%\n5.1-11.5\n92.8%\n\n\nMajor ICH\n7\n117/1287\n6.2%\n2.8-13.0\n91.5%\n\n\nFatal ICH\n11\n13/764\n2.9%\n1.7-4.7\n0%\n\n\nICH in PBC patients\n18\n156/2353\n6.4%\n4.1-9.9\n84.4%\n\n\nICH in MBC patients\n9\n218/1009\n13.0%\n6.5-24.2\n93.7%\n\n\nMajor ICH in PBC patients\n4\n30/793\n3.9%\n1.3-11.6\n87.6%\n\n\nMajor ICH in MBC patients\n3\n87/494\n15.4%\n9.4-24.2\n74.6%\n\n\nICH in patients with VTE\n25\n384/3313\n7.1%\n4.4-11.5\n93.7%\n\n\n\nOpen in a new tab\nMBC, metastatic brain cancer; PBC, primary brain cancer.Rates of ICH in patients with primary brain cancer were reported in 18 studies and ranged from 1.1% to 25.4%.4,9-12,16,18-21,23,27,28,30,31,33-35 The weighted incidence rate was 6.4% (95% CI, 4.1-9.9; I2 = 84.4%; 156 events in 2353 patients) (supplemental Figure 3A), and the risk of publication bias was significant (t = 2.39; P = .03) (supplemental Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Rate of ICH in patients with metastatic brain cancer was reported in 9 studies and ranged from 2.7% to 47.6%.3,5,9,12,14-16,18,26 In these studies, the weighted incidence rate of ICH was 13.0% (95% CI, 6.5-24.2; I2 = 93.7%; 218 events in 1009 patients) (supplemental Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The risk of publication bias was significant (t = 5.10; P = .001); after the trim-and-fill procedure, 2 studies were trimmed, and the adjusted rate of ICH was 17.5% (95% CI, 9.6-29.8) (supplemental Figure 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In patients with primary brain cancer, anticoagulant therapy was associated with an increased risk of ICH and of major ICH (Figure 1; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rates of ICH in patients with primary brain cancer or brain metastases treated with or without anticoagulants\n\n\n\nSetting\nNo. of studies\nNo. of ICH/no. of patients treated\nAnticoagulant therapy\nNo. of ICH/no. of patients not treated\nNo anticoagulant therapy\nRR\n95% CI\n\nP\n\n\nI\n2\n\n\n\n\nOverall patients\n17\n152/1072\n11.5%(95% CI, 7.4-17.6)\n177/1824\n6.0%(95% CI, 3.0-11.5)\n1.81\n1.15-2.84\n.001\n60.3%\n\n\nPatients with PBC\n11\n80/659\n12.5%(95% CI, 8.0-18.8)\n50/1346\n4.4%(95% CI, 2.5-7.7)\n2.58\n1.59-4.19\n<.001\n45.5%\n\n\nPatients with MBC\n4\n61/265\n14.7%(95% CI, 4.4-39.2)\n81/301\n15.4%(95% CI, 5.3-37.2)\n0.86\n0.45-1.65\n.287\n0%\n\n\nPatients treated with DOACs vs LMWH\n5\n12/172\n8.3%(95% CI, 4.4-15.3)\n71/278\n11.7%(95% CI, 2.9-37.0)\n0.44\n0.25-0.79\n.007\n0%\n\n\nPatients treated with LMWH vs warfarin\n4\n15/211\n5.9%(95% CI, 1.5-20.5)\n8/198\n5.4%(95% CI, 1.5-17.3)\n1.45\n0.56-3.79\n.185\n0%\n\n\nOverall major ICH\n4\n33/239\n10.4%(95% CI, 4.0-24.5)\n47/734\n3.4%(95% CI, 0.6-17.6)\n1.93\n0.79-4.73\n.001\n38.7%\n\n\nMajor ICH in patients with PBC\n3\n9/135\n6.3%(95% CI, 1.7-20.3)\n9/545\n1.8%(95% CI, 0.9-3.4)\n3.75\n1.6-4.5\n.003\n0%\n\n\n\nOpen in a new tab\nMBC, metastatic brain cancer; PBC, primary brain cancer.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rate of ICH according to the type of anticoagulant treatment\nIn patients with primary brain cancer or brain metastases, DOACs were associated with a lower risk of ICH than low-molecular weight heparin (LMWH) (8.3% vs 11.7%; RR, 0.44; 95% CI, 0.25-0.79; I2 = 0%; 5 studies in 450 patients) (supplemental Figure 4A).8-10,14,17 In patients with primary brain cancer, DOACs were associated with a reduced risk of ICH (RR, 0.19; 95% CI, 0.04-0.99; I2 = 0%; 0 events in 69 DOAC-treated patients and 19 events in 95 LMWH-treated patients, 4 studies).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "When considering only studies in patients receiving anticoagulants for VTE, the RR for ICH was 0.36 (95% CI, 0.18-0.71; I2 = 0%; 4 studies) in patients treated with DOACs (8 events in 131 patients) compared with LMWH (64 events in 223 patients).9,11,14,16 Risk of ICH was not significantly different with LMWH vs warfarin (4 studies, 15 events in 211 LMWH-treated patients vs 8 events in 198 warfarin-treated patients) (RR, 1.45; 95% CI, 0.56-3.79; I2 = 0%) (supplemental Figure 4B).17,22,23,27Discussion\nThe current meta-analysis provides the following findings: (1) the rate of ICH and major ICH is higher in patients with metastatic brain cancer compared with those with primary brain cancer; (2) anticoagulant therapy is associated with an increase in ICH and major ICH in patients with primary brain cancer but not in those with brain metastases; and (3) the risk of ICH is lower in patients with primary or metastatic brain cancer treated with DOACs compared with those treated with LMWH.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The flow diagram of the literature search is shown in supplemental Figure 1, and the main features of the studies are reported in Table 1 and supplemental Tables 1 and 3.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Bias assessment plots are reported in supplemental Figure 2A.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Rates of ICH, major ICH, and fatal ICH in patients with primary brain cancer or brain metastases\n\n\n\nOutcome\nNo. of studies\nNo. of ICH/no. of patients\nRate\n95% CI\n\nI\n2\n\n\n\n\nOverall ICH\n30\n445/3893\n7.7%\n5.1-11.5\n92.8%\n\n\nMajor ICH\n7\n117/1287\n6.2%\n2.8-13.0\n91.5%\n\n\nFatal ICH\n11\n13/764\n2.9%\n1.7-4.7\n0%\n\n\nICH in PBC patients\n18\n156/2353\n6.4%\n4.1-9.9\n84.4%\n\n\nICH in MBC patients\n9\n218/1009\n13.0%\n6.5-24.2\n93.7%\n\n\nMajor ICH in PBC patients\n4\n30/793\n3.9%\n1.3-11.6\n87.6%\n\n\nMajor ICH in MBC patients\n3\n87/494\n15.4%\n9.4-24.2\n74.6%\n\n\nICH in patients with VTE\n25\n384/3313\n7.1%\n4.4-11.5\n93.7%\n\n\n\nOpen in a new tab\nMBC, metastatic brain cancer; PBC, primary brain cancer.Rates of ICH in patients with primary brain cancer were reported in 18 studies and ranged from 1.1% to 25.4%.4,9-12,16,18-21,23,27,28,30,31,33-35 The weighted incidence rate was 6.4% (95% CI, 4.1-9.9; I2 = 84.4%; 156 events in 2353 patients) (supplemental Figure 3A), and the risk of publication bias was significant (t = 2.39; P = .03) (supplemental Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Rate of ICH in patients with metastatic brain cancer was reported in 9 studies and ranged from 2.7% to 47.6%.3,5,9,12,14-16,18,26 In these studies, the weighted incidence rate of ICH was 13.0% (95% CI, 6.5-24.2; I2 = 93.7%; 218 events in 1009 patients) (supplemental Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The risk of publication bias was significant (t = 5.10; P = .001); after the trim-and-fill procedure, 2 studies were trimmed, and the adjusted rate of ICH was 17.5% (95% CI, 9.6-29.8) (supplemental Figure 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In patients with primary brain cancer, anticoagulant therapy was associated with an increased risk of ICH and of major ICH (Figure 1; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rates of ICH in patients with primary brain cancer or brain metastases treated with or without anticoagulants\n\n\n\nSetting\nNo. of studies\nNo. of ICH/no. of patients treated\nAnticoagulant therapy\nNo. of ICH/no. of patients not treated\nNo anticoagulant therapy\nRR\n95% CI\n\nP\n\n\nI\n2\n\n\n\n\nOverall patients\n17\n152/1072\n11.5%(95% CI, 7.4-17.6)\n177/1824\n6.0%(95% CI, 3.0-11.5)\n1.81\n1.15-2.84\n.001\n60.3%\n\n\nPatients with PBC\n11\n80/659\n12.5%(95% CI, 8.0-18.8)\n50/1346\n4.4%(95% CI, 2.5-7.7)\n2.58\n1.59-4.19\n<.001\n45.5%\n\n\nPatients with MBC\n4\n61/265\n14.7%(95% CI, 4.4-39.2)\n81/301\n15.4%(95% CI, 5.3-37.2)\n0.86\n0.45-1.65\n.287\n0%\n\n\nPatients treated with DOACs vs LMWH\n5\n12/172\n8.3%(95% CI, 4.4-15.3)\n71/278\n11.7%(95% CI, 2.9-37.0)\n0.44\n0.25-0.79\n.007\n0%\n\n\nPatients treated with LMWH vs warfarin\n4\n15/211\n5.9%(95% CI, 1.5-20.5)\n8/198\n5.4%(95% CI, 1.5-17.3)\n1.45\n0.56-3.79\n.185\n0%\n\n\nOverall major ICH\n4\n33/239\n10.4%(95% CI, 4.0-24.5)\n47/734\n3.4%(95% CI, 0.6-17.6)\n1.93\n0.79-4.73\n.001\n38.7%\n\n\nMajor ICH in patients with PBC\n3\n9/135\n6.3%(95% CI, 1.7-20.3)\n9/545\n1.8%(95% CI, 0.9-3.4)\n3.75\n1.6-4.5\n.003\n0%\n\n\n\nOpen in a new tab\nMBC, metastatic brain cancer; PBC, primary brain cancer.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rate of ICH according to the type of anticoagulant treatment\nIn patients with primary brain cancer or brain metastases, DOACs were associated with a lower risk of ICH than low-molecular weight heparin (LMWH) (8.3% vs 11.7%; RR, 0.44; 95% CI, 0.25-0.79; I2 = 0%; 5 studies in 450 patients) (supplemental Figure 4A).8-10,14,17 In patients with primary brain cancer, DOACs were associated with a reduced risk of ICH (RR, 0.19; 95% CI, 0.04-0.99; I2 = 0%; 0 events in 69 DOAC-treated patients and 19 events in 95 LMWH-treated patients, 4 studies).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "When considering only studies in patients receiving anticoagulants for VTE, the RR for ICH was 0.36 (95% CI, 0.18-0.71; I2 = 0%; 4 studies) in patients treated with DOACs (8 events in 131 patients) compared with LMWH (64 events in 223 patients).9,11,14,16 Risk of ICH was not significantly different with LMWH vs warfarin (4 studies, 15 events in 211 LMWH-treated patients vs 8 events in 198 warfarin-treated patients) (RR, 1.45; 95% CI, 0.56-3.79; I2 = 0%) (supplemental Figure 4B).17,22,23,27Discussion\nThe current meta-analysis provides the following findings: (1) the rate of ICH and major ICH is higher in patients with metastatic brain cancer compared with those with primary brain cancer; (2) anticoagulant therapy is associated with an increase in ICH and major ICH in patients with primary brain cancer but not in those with brain metastases; and (3) the risk of ICH is lower in patients with primary or metastatic brain cancer treated with DOACs compared with those treated with LMWH.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The flow diagram of the literature search is shown in supplemental Figure 1, and the main features of the studies are reported in Table 1 and supplemental Tables 1 and 3.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Bias assessment plots are reported in supplemental Figure 2A.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Rates of ICH, major ICH, and fatal ICH in patients with primary brain cancer or brain metastases\n\n\n\nOutcome\nNo. of studies\nNo. of ICH/no. of patients\nRate\n95% CI\n\nI\n2\n\n\n\n\nOverall ICH\n30\n445/3893\n7.7%\n5.1-11.5\n92.8%\n\n\nMajor ICH\n7\n117/1287\n6.2%\n2.8-13.0\n91.5%\n\n\nFatal ICH\n11\n13/764\n2.9%\n1.7-4.7\n0%\n\n\nICH in PBC patients\n18\n156/2353\n6.4%\n4.1-9.9\n84.4%\n\n\nICH in MBC patients\n9\n218/1009\n13.0%\n6.5-24.2\n93.7%\n\n\nMajor ICH in PBC patients\n4\n30/793\n3.9%\n1.3-11.6\n87.6%\n\n\nMajor ICH in MBC patients\n3\n87/494\n15.4%\n9.4-24.2\n74.6%\n\n\nICH in patients with VTE\n25\n384/3313\n7.1%\n4.4-11.5\n93.7%\n\n\n\nOpen in a new tab\nMBC, metastatic brain cancer; PBC, primary brain cancer.Rates of ICH in patients with primary brain cancer were reported in 18 studies and ranged from 1.1% to 25.4%.4,9-12,16,18-21,23,27,28,30,31,33-35 The weighted incidence rate was 6.4% (95% CI, 4.1-9.9; I2 = 84.4%; 156 events in 2353 patients) (supplemental Figure 3A), and the risk of publication bias was significant (t = 2.39; P = .03) (supplemental Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Rate of ICH in patients with metastatic brain cancer was reported in 9 studies and ranged from 2.7% to 47.6%.3,5,9,12,14-16,18,26 In these studies, the weighted incidence rate of ICH was 13.0% (95% CI, 6.5-24.2; I2 = 93.7%; 218 events in 1009 patients) (supplemental Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The risk of publication bias was significant (t = 5.10; P = .001); after the trim-and-fill procedure, 2 studies were trimmed, and the adjusted rate of ICH was 17.5% (95% CI, 9.6-29.8) (supplemental Figure 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In patients with primary brain cancer, anticoagulant therapy was associated with an increased risk of ICH and of major ICH (Figure 1; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rates of ICH in patients with primary brain cancer or brain metastases treated with or without anticoagulants\n\n\n\nSetting\nNo. of studies\nNo. of ICH/no. of patients treated\nAnticoagulant therapy\nNo. of ICH/no. of patients not treated\nNo anticoagulant therapy\nRR\n95% CI\n\nP\n\n\nI\n2\n\n\n\n\nOverall patients\n17\n152/1072\n11.5%(95% CI, 7.4-17.6)\n177/1824\n6.0%(95% CI, 3.0-11.5)\n1.81\n1.15-2.84\n.001\n60.3%\n\n\nPatients with PBC\n11\n80/659\n12.5%(95% CI, 8.0-18.8)\n50/1346\n4.4%(95% CI, 2.5-7.7)\n2.58\n1.59-4.19\n<.001\n45.5%\n\n\nPatients with MBC\n4\n61/265\n14.7%(95% CI, 4.4-39.2)\n81/301\n15.4%(95% CI, 5.3-37.2)\n0.86\n0.45-1.65\n.287\n0%\n\n\nPatients treated with DOACs vs LMWH\n5\n12/172\n8.3%(95% CI, 4.4-15.3)\n71/278\n11.7%(95% CI, 2.9-37.0)\n0.44\n0.25-0.79\n.007\n0%\n\n\nPatients treated with LMWH vs warfarin\n4\n15/211\n5.9%(95% CI, 1.5-20.5)\n8/198\n5.4%(95% CI, 1.5-17.3)\n1.45\n0.56-3.79\n.185\n0%\n\n\nOverall major ICH\n4\n33/239\n10.4%(95% CI, 4.0-24.5)\n47/734\n3.4%(95% CI, 0.6-17.6)\n1.93\n0.79-4.73\n.001\n38.7%\n\n\nMajor ICH in patients with PBC\n3\n9/135\n6.3%(95% CI, 1.7-20.3)\n9/545\n1.8%(95% CI, 0.9-3.4)\n3.75\n1.6-4.5\n.003\n0%\n\n\n\nOpen in a new tab\nMBC, metastatic brain cancer; PBC, primary brain cancer.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rate of ICH according to the type of anticoagulant treatment\nIn patients with primary brain cancer or brain metastases, DOACs were associated with a lower risk of ICH than low-molecular weight heparin (LMWH) (8.3% vs 11.7%; RR, 0.44; 95% CI, 0.25-0.79; I2 = 0%; 5 studies in 450 patients) (supplemental Figure 4A).8-10,14,17 In patients with primary brain cancer, DOACs were associated with a reduced risk of ICH (RR, 0.19; 95% CI, 0.04-0.99; I2 = 0%; 0 events in 69 DOAC-treated patients and 19 events in 95 LMWH-treated patients, 4 studies).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "When considering only studies in patients receiving anticoagulants for VTE, the RR for ICH was 0.36 (95% CI, 0.18-0.71; I2 = 0%; 4 studies) in patients treated with DOACs (8 events in 131 patients) compared with LMWH (64 events in 223 patients).9,11,14,16 Risk of ICH was not significantly different with LMWH vs warfarin (4 studies, 15 events in 211 LMWH-treated patients vs 8 events in 198 warfarin-treated patients) (RR, 1.45; 95% CI, 0.56-3.79; I2 = 0%) (supplemental Figure 4B).17,22,23,27Discussion\nThe current meta-analysis provides the following findings: (1) the rate of ICH and major ICH is higher in patients with metastatic brain cancer compared with those with primary brain cancer; (2) anticoagulant therapy is associated with an increase in ICH and major ICH in patients with primary brain cancer but not in those with brain metastases; and (3) the risk of ICH is lower in patients with primary or metastatic brain cancer treated with DOACs compared with those treated with LMWH.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The flow diagram of the literature search is shown in supplemental Figure 1, and the main features of the studies are reported in Table 1 and supplemental Tables 1 and 3.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Bias assessment plots are reported in supplemental Figure 2A.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Rates of ICH, major ICH, and fatal ICH in patients with primary brain cancer or brain metastases\n\n\n\nOutcome\nNo. of studies\nNo. of ICH/no. of patients\nRate\n95% CI\n\nI\n2\n\n\n\n\nOverall ICH\n30\n445/3893\n7.7%\n5.1-11.5\n92.8%\n\n\nMajor ICH\n7\n117/1287\n6.2%\n2.8-13.0\n91.5%\n\n\nFatal ICH\n11\n13/764\n2.9%\n1.7-4.7\n0%\n\n\nICH in PBC patients\n18\n156/2353\n6.4%\n4.1-9.9\n84.4%\n\n\nICH in MBC patients\n9\n218/1009\n13.0%\n6.5-24.2\n93.7%\n\n\nMajor ICH in PBC patients\n4\n30/793\n3.9%\n1.3-11.6\n87.6%\n\n\nMajor ICH in MBC patients\n3\n87/494\n15.4%\n9.4-24.2\n74.6%\n\n\nICH in patients with VTE\n25\n384/3313\n7.1%\n4.4-11.5\n93.7%\n\n\n\nOpen in a new tab\nMBC, metastatic brain cancer; PBC, primary brain cancer.Rates of ICH in patients with primary brain cancer were reported in 18 studies and ranged from 1.1% to 25.4%.4,9-12,16,18-21,23,27,28,30,31,33-35 The weighted incidence rate was 6.4% (95% CI, 4.1-9.9; I2 = 84.4%; 156 events in 2353 patients) (supplemental Figure 3A), and the risk of publication bias was significant (t = 2.39; P = .03) (supplemental Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Rate of ICH in patients with metastatic brain cancer was reported in 9 studies and ranged from 2.7% to 47.6%.3,5,9,12,14-16,18,26 In these studies, the weighted incidence rate of ICH was 13.0% (95% CI, 6.5-24.2; I2 = 93.7%; 218 events in 1009 patients) (supplemental Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The risk of publication bias was significant (t = 5.10; P = .001); after the trim-and-fill procedure, 2 studies were trimmed, and the adjusted rate of ICH was 17.5% (95% CI, 9.6-29.8) (supplemental Figure 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In patients with primary brain cancer, anticoagulant therapy was associated with an increased risk of ICH and of major ICH (Figure 1; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rates of ICH in patients with primary brain cancer or brain metastases treated with or without anticoagulants\n\n\n\nSetting\nNo. of studies\nNo. of ICH/no. of patients treated\nAnticoagulant therapy\nNo. of ICH/no. of patients not treated\nNo anticoagulant therapy\nRR\n95% CI\n\nP\n\n\nI\n2\n\n\n\n\nOverall patients\n17\n152/1072\n11.5%(95% CI, 7.4-17.6)\n177/1824\n6.0%(95% CI, 3.0-11.5)\n1.81\n1.15-2.84\n.001\n60.3%\n\n\nPatients with PBC\n11\n80/659\n12.5%(95% CI, 8.0-18.8)\n50/1346\n4.4%(95% CI, 2.5-7.7)\n2.58\n1.59-4.19\n<.001\n45.5%\n\n\nPatients with MBC\n4\n61/265\n14.7%(95% CI, 4.4-39.2)\n81/301\n15.4%(95% CI, 5.3-37.2)\n0.86\n0.45-1.65\n.287\n0%\n\n\nPatients treated with DOACs vs LMWH\n5\n12/172\n8.3%(95% CI, 4.4-15.3)\n71/278\n11.7%(95% CI, 2.9-37.0)\n0.44\n0.25-0.79\n.007\n0%\n\n\nPatients treated with LMWH vs warfarin\n4\n15/211\n5.9%(95% CI, 1.5-20.5)\n8/198\n5.4%(95% CI, 1.5-17.3)\n1.45\n0.56-3.79\n.185\n0%\n\n\nOverall major ICH\n4\n33/239\n10.4%(95% CI, 4.0-24.5)\n47/734\n3.4%(95% CI, 0.6-17.6)\n1.93\n0.79-4.73\n.001\n38.7%\n\n\nMajor ICH in patients with PBC\n3\n9/135\n6.3%(95% CI, 1.7-20.3)\n9/545\n1.8%(95% CI, 0.9-3.4)\n3.75\n1.6-4.5\n.003\n0%\n\n\n\nOpen in a new tab\nMBC, metastatic brain cancer; PBC, primary brain cancer.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rate of ICH according to the type of anticoagulant treatment\nIn patients with primary brain cancer or brain metastases, DOACs were associated with a lower risk of ICH than low-molecular weight heparin (LMWH) (8.3% vs 11.7%; RR, 0.44; 95% CI, 0.25-0.79; I2 = 0%; 5 studies in 450 patients) (supplemental Figure 4A).8-10,14,17 In patients with primary brain cancer, DOACs were associated with a reduced risk of ICH (RR, 0.19; 95% CI, 0.04-0.99; I2 = 0%; 0 events in 69 DOAC-treated patients and 19 events in 95 LMWH-treated patients, 4 studies).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "When considering only studies in patients receiving anticoagulants for VTE, the RR for ICH was 0.36 (95% CI, 0.18-0.71; I2 = 0%; 4 studies) in patients treated with DOACs (8 events in 131 patients) compared with LMWH (64 events in 223 patients).9,11,14,16 Risk of ICH was not significantly different with LMWH vs warfarin (4 studies, 15 events in 211 LMWH-treated patients vs 8 events in 198 warfarin-treated patients) (RR, 1.45; 95% CI, 0.56-3.79; I2 = 0%) (supplemental Figure 4B).17,22,23,27Discussion\nThe current meta-analysis provides the following findings: (1) the rate of ICH and major ICH is higher in patients with metastatic brain cancer compared with those with primary brain cancer; (2) anticoagulant therapy is associated with an increase in ICH and major ICH in patients with primary brain cancer but not in those with brain metastases; and (3) the risk of ICH is lower in patients with primary or metastatic brain cancer treated with DOACs compared with those treated with LMWH.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The flow diagram of the literature search is shown in supplemental Figure 1, and the main features of the studies are reported in Table 1 and supplemental Tables 1 and 3.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Bias assessment plots are reported in supplemental Figure 2A.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Rates of ICH, major ICH, and fatal ICH in patients with primary brain cancer or brain metastases\n\n\n\nOutcome\nNo. of studies\nNo. of ICH/no. of patients\nRate\n95% CI\n\nI\n2\n\n\n\n\nOverall ICH\n30\n445/3893\n7.7%\n5.1-11.5\n92.8%\n\n\nMajor ICH\n7\n117/1287\n6.2%\n2.8-13.0\n91.5%\n\n\nFatal ICH\n11\n13/764\n2.9%\n1.7-4.7\n0%\n\n\nICH in PBC patients\n18\n156/2353\n6.4%\n4.1-9.9\n84.4%\n\n\nICH in MBC patients\n9\n218/1009\n13.0%\n6.5-24.2\n93.7%\n\n\nMajor ICH in PBC patients\n4\n30/793\n3.9%\n1.3-11.6\n87.6%\n\n\nMajor ICH in MBC patients\n3\n87/494\n15.4%\n9.4-24.2\n74.6%\n\n\nICH in patients with VTE\n25\n384/3313\n7.1%\n4.4-11.5\n93.7%\n\n\n\nOpen in a new tab\nMBC, metastatic brain cancer; PBC, primary brain cancer.Rates of ICH in patients with primary brain cancer were reported in 18 studies and ranged from 1.1% to 25.4%.4,9-12,16,18-21,23,27,28,30,31,33-35 The weighted incidence rate was 6.4% (95% CI, 4.1-9.9; I2 = 84.4%; 156 events in 2353 patients) (supplemental Figure 3A), and the risk of publication bias was significant (t = 2.39; P = .03) (supplemental Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Rate of ICH in patients with metastatic brain cancer was reported in 9 studies and ranged from 2.7% to 47.6%.3,5,9,12,14-16,18,26 In these studies, the weighted incidence rate of ICH was 13.0% (95% CI, 6.5-24.2; I2 = 93.7%; 218 events in 1009 patients) (supplemental Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The risk of publication bias was significant (t = 5.10; P = .001); after the trim-and-fill procedure, 2 studies were trimmed, and the adjusted rate of ICH was 17.5% (95% CI, 9.6-29.8) (supplemental Figure 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In patients with primary brain cancer, anticoagulant therapy was associated with an increased risk of ICH and of major ICH (Figure 1; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rates of ICH in patients with primary brain cancer or brain metastases treated with or without anticoagulants\n\n\n\nSetting\nNo. of studies\nNo. of ICH/no. of patients treated\nAnticoagulant therapy\nNo. of ICH/no. of patients not treated\nNo anticoagulant therapy\nRR\n95% CI\n\nP\n\n\nI\n2\n\n\n\n\nOverall patients\n17\n152/1072\n11.5%(95% CI, 7.4-17.6)\n177/1824\n6.0%(95% CI, 3.0-11.5)\n1.81\n1.15-2.84\n.001\n60.3%\n\n\nPatients with PBC\n11\n80/659\n12.5%(95% CI, 8.0-18.8)\n50/1346\n4.4%(95% CI, 2.5-7.7)\n2.58\n1.59-4.19\n<.001\n45.5%\n\n\nPatients with MBC\n4\n61/265\n14.7%(95% CI, 4.4-39.2)\n81/301\n15.4%(95% CI, 5.3-37.2)\n0.86\n0.45-1.65\n.287\n0%\n\n\nPatients treated with DOACs vs LMWH\n5\n12/172\n8.3%(95% CI, 4.4-15.3)\n71/278\n11.7%(95% CI, 2.9-37.0)\n0.44\n0.25-0.79\n.007\n0%\n\n\nPatients treated with LMWH vs warfarin\n4\n15/211\n5.9%(95% CI, 1.5-20.5)\n8/198\n5.4%(95% CI, 1.5-17.3)\n1.45\n0.56-3.79\n.185\n0%\n\n\nOverall major ICH\n4\n33/239\n10.4%(95% CI, 4.0-24.5)\n47/734\n3.4%(95% CI, 0.6-17.6)\n1.93\n0.79-4.73\n.001\n38.7%\n\n\nMajor ICH in patients with PBC\n3\n9/135\n6.3%(95% CI, 1.7-20.3)\n9/545\n1.8%(95% CI, 0.9-3.4)\n3.75\n1.6-4.5\n.003\n0%\n\n\n\nOpen in a new tab\nMBC, metastatic brain cancer; PBC, primary brain cancer.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rate of ICH according to the type of anticoagulant treatment\nIn patients with primary brain cancer or brain metastases, DOACs were associated with a lower risk of ICH than low-molecular weight heparin (LMWH) (8.3% vs 11.7%; RR, 0.44; 95% CI, 0.25-0.79; I2 = 0%; 5 studies in 450 patients) (supplemental Figure 4A).8-10,14,17 In patients with primary brain cancer, DOACs were associated with a reduced risk of ICH (RR, 0.19; 95% CI, 0.04-0.99; I2 = 0%; 0 events in 69 DOAC-treated patients and 19 events in 95 LMWH-treated patients, 4 studies).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "When considering only studies in patients receiving anticoagulants for VTE, the RR for ICH was 0.36 (95% CI, 0.18-0.71; I2 = 0%; 4 studies) in patients treated with DOACs (8 events in 131 patients) compared with LMWH (64 events in 223 patients).9,11,14,16 Risk of ICH was not significantly different with LMWH vs warfarin (4 studies, 15 events in 211 LMWH-treated patients vs 8 events in 198 warfarin-treated patients) (RR, 1.45; 95% CI, 0.56-3.79; I2 = 0%) (supplemental Figure 4B).17,22,23,27Discussion\nThe current meta-analysis provides the following findings: (1) the rate of ICH and major ICH is higher in patients with metastatic brain cancer compared with those with primary brain cancer; (2) anticoagulant therapy is associated with an increase in ICH and major ICH in patients with primary brain cancer but not in those with brain metastases; and (3) the risk of ICH is lower in patients with primary or metastatic brain cancer treated with DOACs compared with those treated with LMWH.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The flow diagram of the literature search is shown in supplemental Figure 1, and the main features of the studies are reported in Table 1 and supplemental Tables 1 and 3.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Bias assessment plots are reported in supplemental Figure 2A.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Rates of ICH, major ICH, and fatal ICH in patients with primary brain cancer or brain metastases\n\n\n\nOutcome\nNo. of studies\nNo. of ICH/no. of patients\nRate\n95% CI\n\nI\n2\n\n\n\n\nOverall ICH\n30\n445/3893\n7.7%\n5.1-11.5\n92.8%\n\n\nMajor ICH\n7\n117/1287\n6.2%\n2.8-13.0\n91.5%\n\n\nFatal ICH\n11\n13/764\n2.9%\n1.7-4.7\n0%\n\n\nICH in PBC patients\n18\n156/2353\n6.4%\n4.1-9.9\n84.4%\n\n\nICH in MBC patients\n9\n218/1009\n13.0%\n6.5-24.2\n93.7%\n\n\nMajor ICH in PBC patients\n4\n30/793\n3.9%\n1.3-11.6\n87.6%\n\n\nMajor ICH in MBC patients\n3\n87/494\n15.4%\n9.4-24.2\n74.6%\n\n\nICH in patients with VTE\n25\n384/3313\n7.1%\n4.4-11.5\n93.7%\n\n\n\nOpen in a new tab\nMBC, metastatic brain cancer; PBC, primary brain cancer.Rates of ICH in patients with primary brain cancer were reported in 18 studies and ranged from 1.1% to 25.4%.4,9-12,16,18-21,23,27,28,30,31,33-35 The weighted incidence rate was 6.4% (95% CI, 4.1-9.9; I2 = 84.4%; 156 events in 2353 patients) (supplemental Figure 3A), and the risk of publication bias was significant (t = 2.39; P = .03) (supplemental Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Rate of ICH in patients with metastatic brain cancer was reported in 9 studies and ranged from 2.7% to 47.6%.3,5,9,12,14-16,18,26 In these studies, the weighted incidence rate of ICH was 13.0% (95% CI, 6.5-24.2; I2 = 93.7%; 218 events in 1009 patients) (supplemental Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The risk of publication bias was significant (t = 5.10; P = .001); after the trim-and-fill procedure, 2 studies were trimmed, and the adjusted rate of ICH was 17.5% (95% CI, 9.6-29.8) (supplemental Figure 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In patients with primary brain cancer, anticoagulant therapy was associated with an increased risk of ICH and of major ICH (Figure 1; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rates of ICH in patients with primary brain cancer or brain metastases treated with or without anticoagulants\n\n\n\nSetting\nNo. of studies\nNo. of ICH/no. of patients treated\nAnticoagulant therapy\nNo. of ICH/no. of patients not treated\nNo anticoagulant therapy\nRR\n95% CI\n\nP\n\n\nI\n2\n\n\n\n\nOverall patients\n17\n152/1072\n11.5%(95% CI, 7.4-17.6)\n177/1824\n6.0%(95% CI, 3.0-11.5)\n1.81\n1.15-2.84\n.001\n60.3%\n\n\nPatients with PBC\n11\n80/659\n12.5%(95% CI, 8.0-18.8)\n50/1346\n4.4%(95% CI, 2.5-7.7)\n2.58\n1.59-4.19\n<.001\n45.5%\n\n\nPatients with MBC\n4\n61/265\n14.7%(95% CI, 4.4-39.2)\n81/301\n15.4%(95% CI, 5.3-37.2)\n0.86\n0.45-1.65\n.287\n0%\n\n\nPatients treated with DOACs vs LMWH\n5\n12/172\n8.3%(95% CI, 4.4-15.3)\n71/278\n11.7%(95% CI, 2.9-37.0)\n0.44\n0.25-0.79\n.007\n0%\n\n\nPatients treated with LMWH vs warfarin\n4\n15/211\n5.9%(95% CI, 1.5-20.5)\n8/198\n5.4%(95% CI, 1.5-17.3)\n1.45\n0.56-3.79\n.185\n0%\n\n\nOverall major ICH\n4\n33/239\n10.4%(95% CI, 4.0-24.5)\n47/734\n3.4%(95% CI, 0.6-17.6)\n1.93\n0.79-4.73\n.001\n38.7%\n\n\nMajor ICH in patients with PBC\n3\n9/135\n6.3%(95% CI, 1.7-20.3)\n9/545\n1.8%(95% CI, 0.9-3.4)\n3.75\n1.6-4.5\n.003\n0%\n\n\n\nOpen in a new tab\nMBC, metastatic brain cancer; PBC, primary brain cancer.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rate of ICH according to the type of anticoagulant treatment\nIn patients with primary brain cancer or brain metastases, DOACs were associated with a lower risk of ICH than low-molecular weight heparin (LMWH) (8.3% vs 11.7%; RR, 0.44; 95% CI, 0.25-0.79; I2 = 0%; 5 studies in 450 patients) (supplemental Figure 4A).8-10,14,17 In patients with primary brain cancer, DOACs were associated with a reduced risk of ICH (RR, 0.19; 95% CI, 0.04-0.99; I2 = 0%; 0 events in 69 DOAC-treated patients and 19 events in 95 LMWH-treated patients, 4 studies).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "When considering only studies in patients receiving anticoagulants for VTE, the RR for ICH was 0.36 (95% CI, 0.18-0.71; I2 = 0%; 4 studies) in patients treated with DOACs (8 events in 131 patients) compared with LMWH (64 events in 223 patients).9,11,14,16 Risk of ICH was not significantly different with LMWH vs warfarin (4 studies, 15 events in 211 LMWH-treated patients vs 8 events in 198 warfarin-treated patients) (RR, 1.45; 95% CI, 0.56-3.79; I2 = 0%) (supplemental Figure 4B).17,22,23,27Discussion\nThe current meta-analysis provides the following findings: (1) the rate of ICH and major ICH is higher in patients with metastatic brain cancer compared with those with primary brain cancer; (2) anticoagulant therapy is associated with an increase in ICH and major ICH in patients with primary brain cancer but not in those with brain metastases; and (3) the risk of ICH is lower in patients with primary or metastatic brain cancer treated with DOACs compared with those treated with LMWH.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The flow diagram of the literature search is shown in supplemental Figure 1, and the main features of the studies are reported in Table 1 and supplemental Tables 1 and 3.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Bias assessment plots are reported in supplemental Figure 2A.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Rates of ICH, major ICH, and fatal ICH in patients with primary brain cancer or brain metastases\n\n\n\nOutcome\nNo. of studies\nNo. of ICH/no. of patients\nRate\n95% CI\n\nI\n2\n\n\n\n\nOverall ICH\n30\n445/3893\n7.7%\n5.1-11.5\n92.8%\n\n\nMajor ICH\n7\n117/1287\n6.2%\n2.8-13.0\n91.5%\n\n\nFatal ICH\n11\n13/764\n2.9%\n1.7-4.7\n0%\n\n\nICH in PBC patients\n18\n156/2353\n6.4%\n4.1-9.9\n84.4%\n\n\nICH in MBC patients\n9\n218/1009\n13.0%\n6.5-24.2\n93.7%\n\n\nMajor ICH in PBC patients\n4\n30/793\n3.9%\n1.3-11.6\n87.6%\n\n\nMajor ICH in MBC patients\n3\n87/494\n15.4%\n9.4-24.2\n74.6%\n\n\nICH in patients with VTE\n25\n384/3313\n7.1%\n4.4-11.5\n93.7%\n\n\n\nOpen in a new tab\nMBC, metastatic brain cancer; PBC, primary brain cancer.Rates of ICH in patients with primary brain cancer were reported in 18 studies and ranged from 1.1% to 25.4%.4,9-12,16,18-21,23,27,28,30,31,33-35 The weighted incidence rate was 6.4% (95% CI, 4.1-9.9; I2 = 84.4%; 156 events in 2353 patients) (supplemental Figure 3A), and the risk of publication bias was significant (t = 2.39; P = .03) (supplemental Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Rate of ICH in patients with metastatic brain cancer was reported in 9 studies and ranged from 2.7% to 47.6%.3,5,9,12,14-16,18,26 In these studies, the weighted incidence rate of ICH was 13.0% (95% CI, 6.5-24.2; I2 = 93.7%; 218 events in 1009 patients) (supplemental Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The risk of publication bias was significant (t = 5.10; P = .001); after the trim-and-fill procedure, 2 studies were trimmed, and the adjusted rate of ICH was 17.5% (95% CI, 9.6-29.8) (supplemental Figure 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In patients with primary brain cancer, anticoagulant therapy was associated with an increased risk of ICH and of major ICH (Figure 1; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rates of ICH in patients with primary brain cancer or brain metastases treated with or without anticoagulants\n\n\n\nSetting\nNo. of studies\nNo. of ICH/no. of patients treated\nAnticoagulant therapy\nNo. of ICH/no. of patients not treated\nNo anticoagulant therapy\nRR\n95% CI\n\nP\n\n\nI\n2\n\n\n\n\nOverall patients\n17\n152/1072\n11.5%(95% CI, 7.4-17.6)\n177/1824\n6.0%(95% CI, 3.0-11.5)\n1.81\n1.15-2.84\n.001\n60.3%\n\n\nPatients with PBC\n11\n80/659\n12.5%(95% CI, 8.0-18.8)\n50/1346\n4.4%(95% CI, 2.5-7.7)\n2.58\n1.59-4.19\n<.001\n45.5%\n\n\nPatients with MBC\n4\n61/265\n14.7%(95% CI, 4.4-39.2)\n81/301\n15.4%(95% CI, 5.3-37.2)\n0.86\n0.45-1.65\n.287\n0%\n\n\nPatients treated with DOACs vs LMWH\n5\n12/172\n8.3%(95% CI, 4.4-15.3)\n71/278\n11.7%(95% CI, 2.9-37.0)\n0.44\n0.25-0.79\n.007\n0%\n\n\nPatients treated with LMWH vs warfarin\n4\n15/211\n5.9%(95% CI, 1.5-20.5)\n8/198\n5.4%(95% CI, 1.5-17.3)\n1.45\n0.56-3.79\n.185\n0%\n\n\nOverall major ICH\n4\n33/239\n10.4%(95% CI, 4.0-24.5)\n47/734\n3.4%(95% CI, 0.6-17.6)\n1.93\n0.79-4.73\n.001\n38.7%\n\n\nMajor ICH in patients with PBC\n3\n9/135\n6.3%(95% CI, 1.7-20.3)\n9/545\n1.8%(95% CI, 0.9-3.4)\n3.75\n1.6-4.5\n.003\n0%\n\n\n\nOpen in a new tab\nMBC, metastatic brain cancer; PBC, primary brain cancer.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rate of ICH according to the type of anticoagulant treatment\nIn patients with primary brain cancer or brain metastases, DOACs were associated with a lower risk of ICH than low-molecular weight heparin (LMWH) (8.3% vs 11.7%; RR, 0.44; 95% CI, 0.25-0.79; I2 = 0%; 5 studies in 450 patients) (supplemental Figure 4A).8-10,14,17 In patients with primary brain cancer, DOACs were associated with a reduced risk of ICH (RR, 0.19; 95% CI, 0.04-0.99; I2 = 0%; 0 events in 69 DOAC-treated patients and 19 events in 95 LMWH-treated patients, 4 studies).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "When considering only studies in patients receiving anticoagulants for VTE, the RR for ICH was 0.36 (95% CI, 0.18-0.71; I2 = 0%; 4 studies) in patients treated with DOACs (8 events in 131 patients) compared with LMWH (64 events in 223 patients).9,11,14,16 Risk of ICH was not significantly different with LMWH vs warfarin (4 studies, 15 events in 211 LMWH-treated patients vs 8 events in 198 warfarin-treated patients) (RR, 1.45; 95% CI, 0.56-3.79; I2 = 0%) (supplemental Figure 4B).17,22,23,27.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The flow diagram of the literature search is shown in supplemental Figure 1, and the main features of the studies are reported in Table 1 and supplemental Tables 1 and 3.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Bias assessment plots are reported in supplemental Figure 2A.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Rates of ICH, major ICH, and fatal ICH in patients with primary brain cancer or brain metastases\n\n\n\nOutcome\nNo. of studies\nNo. of ICH/no. of patients\nRate\n95% CI\n\nI\n2\n\n\n\n\nOverall ICH\n30\n445/3893\n7.7%\n5.1-11.5\n92.8%\n\n\nMajor ICH\n7\n117/1287\n6.2%\n2.8-13.0\n91.5%\n\n\nFatal ICH\n11\n13/764\n2.9%\n1.7-4.7\n0%\n\n\nICH in PBC patients\n18\n156/2353\n6.4%\n4.1-9.9\n84.4%\n\n\nICH in MBC patients\n9\n218/1009\n13.0%\n6.5-24.2\n93.7%\n\n\nMajor ICH in PBC patients\n4\n30/793\n3.9%\n1.3-11.6\n87.6%\n\n\nMajor ICH in MBC patients\n3\n87/494\n15.4%\n9.4-24.2\n74.6%\n\n\nICH in patients with VTE\n25\n384/3313\n7.1%\n4.4-11.5\n93.7%\n\n\n\nOpen in a new tab\nMBC, metastatic brain cancer; PBC, primary brain cancer.Rates of ICH in patients with primary brain cancer were reported in 18 studies and ranged from 1.1% to 25.4%.4,9-12,16,18-21,23,27,28,30,31,33-35 The weighted incidence rate was 6.4% (95% CI, 4.1-9.9; I2 = 84.4%; 156 events in 2353 patients) (supplemental Figure 3A), and the risk of publication bias was significant (t = 2.39; P = .03) (supplemental Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Rate of ICH in patients with metastatic brain cancer was reported in 9 studies and ranged from 2.7% to 47.6%.3,5,9,12,14-16,18,26 In these studies, the weighted incidence rate of ICH was 13.0% (95% CI, 6.5-24.2; I2 = 93.7%; 218 events in 1009 patients) (supplemental Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The risk of publication bias was significant (t = 5.10; P = .001); after the trim-and-fill procedure, 2 studies were trimmed, and the adjusted rate of ICH was 17.5% (95% CI, 9.6-29.8) (supplemental Figure 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Bias assessment plots are reported in supplemental Figure 2A.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Rates of ICH in patients with primary brain cancer were reported in 18 studies and ranged from 1.1% to 25.4%.4,9-12,16,18-21,23,27,28,30,31,33-35 The weighted incidence rate was 6.4% (95% CI, 4.1-9.9; I2 = 84.4%; 156 events in 2353 patients) (supplemental Figure 3A), and the risk of publication bias was significant (t = 2.39; P = .03) (supplemental Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Rate of ICH in patients with metastatic brain cancer was reported in 9 studies and ranged from 2.7% to 47.6%.3,5,9,12,14-16,18,26 In these studies, the weighted incidence rate of ICH was 13.0% (95% CI, 6.5-24.2; I2 = 93.7%; 218 events in 1009 patients) (supplemental Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The risk of publication bias was significant (t = 5.10; P = .001); after the trim-and-fill procedure, 2 studies were trimmed, and the adjusted rate of ICH was 17.5% (95% CI, 9.6-29.8) (supplemental Figure 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In patients with primary brain cancer, anticoagulant therapy was associated with an increased risk of ICH and of major ICH (Figure 1; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rates of ICH in patients with primary brain cancer or brain metastases treated with or without anticoagulants\n\n\n\nSetting\nNo. of studies\nNo. of ICH/no. of patients treated\nAnticoagulant therapy\nNo. of ICH/no. of patients not treated\nNo anticoagulant therapy\nRR\n95% CI\n\nP\n\n\nI\n2\n\n\n\n\nOverall patients\n17\n152/1072\n11.5%(95% CI, 7.4-17.6)\n177/1824\n6.0%(95% CI, 3.0-11.5)\n1.81\n1.15-2.84\n.001\n60.3%\n\n\nPatients with PBC\n11\n80/659\n12.5%(95% CI, 8.0-18.8)\n50/1346\n4.4%(95% CI, 2.5-7.7)\n2.58\n1.59-4.19\n<.001\n45.5%\n\n\nPatients with MBC\n4\n61/265\n14.7%(95% CI, 4.4-39.2)\n81/301\n15.4%(95% CI, 5.3-37.2)\n0.86\n0.45-1.65\n.287\n0%\n\n\nPatients treated with DOACs vs LMWH\n5\n12/172\n8.3%(95% CI, 4.4-15.3)\n71/278\n11.7%(95% CI, 2.9-37.0)\n0.44\n0.25-0.79\n.007\n0%\n\n\nPatients treated with LMWH vs warfarin\n4\n15/211\n5.9%(95% CI, 1.5-20.5)\n8/198\n5.4%(95% CI, 1.5-17.3)\n1.45\n0.56-3.79\n.185\n0%\n\n\nOverall major ICH\n4\n33/239\n10.4%(95% CI, 4.0-24.5)\n47/734\n3.4%(95% CI, 0.6-17.6)\n1.93\n0.79-4.73\n.001\n38.7%\n\n\nMajor ICH in patients with PBC\n3\n9/135\n6.3%(95% CI, 1.7-20.3)\n9/545\n1.8%(95% CI, 0.9-3.4)\n3.75\n1.6-4.5\n.003\n0%\n\n\n\nOpen in a new tab\nMBC, metastatic brain cancer; PBC, primary brain cancer.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In patients with primary brain cancer, anticoagulant therapy was associated with an increased risk of ICH and of major ICH (Figure 1; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rate of ICH according to the type of anticoagulant treatment\nIn patients with primary brain cancer or brain metastases, DOACs were associated with a lower risk of ICH than low-molecular weight heparin (LMWH) (8.3% vs 11.7%; RR, 0.44; 95% CI, 0.25-0.79; I2 = 0%; 5 studies in 450 patients) (supplemental Figure 4A).8-10,14,17 In patients with primary brain cancer, DOACs were associated with a reduced risk of ICH (RR, 0.19; 95% CI, 0.04-0.99; I2 = 0%; 0 events in 69 DOAC-treated patients and 19 events in 95 LMWH-treated patients, 4 studies).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "When considering only studies in patients receiving anticoagulants for VTE, the RR for ICH was 0.36 (95% CI, 0.18-0.71; I2 = 0%; 4 studies) in patients treated with DOACs (8 events in 131 patients) compared with LMWH (64 events in 223 patients).9,11,14,16 Risk of ICH was not significantly different with LMWH vs warfarin (4 studies, 15 events in 211 LMWH-treated patients vs 8 events in 198 warfarin-treated patients) (RR, 1.45; 95% CI, 0.56-3.79; I2 = 0%) (supplemental Figure 4B).17,22,23,27.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In patients with primary brain cancer or brain metastases, DOACs were associated with a lower risk of ICH than low-molecular weight heparin (LMWH) (8.3% vs 11.7%; RR, 0.44; 95% CI, 0.25-0.79; I2 = 0%; 5 studies in 450 patients) (supplemental Figure 4A).8-10,14,17 In patients with primary brain cancer, DOACs were associated with a reduced risk of ICH (RR, 0.19; 95% CI, 0.04-0.99; I2 = 0%; 0 events in 69 DOAC-treated patients and 19 events in 95 LMWH-treated patients, 4 studies).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "When considering only studies in patients receiving anticoagulants for VTE, the RR for ICH was 0.36 (95% CI, 0.18-0.71; I2 = 0%; 4 studies) in patients treated with DOACs (8 events in 131 patients) compared with LMWH (64 events in 223 patients).9,11,14,16 Risk of ICH was not significantly different with LMWH vs warfarin (4 studies, 15 events in 211 LMWH-treated patients vs 8 events in 198 warfarin-treated patients) (RR, 1.45; 95% CI, 0.56-3.79; I2 = 0%) (supplemental Figure 4B).17,22,23,27.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 1,
    "claims_count": 97,
    "images_downloaded": 1,
    "tables_filtered": 17
  }
}